In-house roundup: 5G licensing challenges; second medical use solutions; PTAB tactics against NPEs; dosage regimen inventive step

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

In-house roundup: 5G licensing challenges; second medical use solutions; PTAB tactics against NPEs; dosage regimen inventive step

effbdf

Managing IP rounds up the latest news and analysis from patent-focused businesses on 5G, the PTAB, inventive step and second medical use reform

effbdf

5G set to exacerbate FRAND problems, say top patent holders

With more diverse non-telecoms businesses using 5G tech, licensing discussions for standard essential patents are likely to increase and become more difficult to negotiate, leading patentees to promote better licensing education. Read More... 

Prescription reform needed to avoid second medical use infringement

Generic and innovator in-house lawyers agree that serious reform to the way medications are prescribed is needed to avoid patent infringement on secondary uses, and that they will need to work together to make that change. Read more... 

How tech companies use the PTAB to fight patent trolls

Senior sources from high-tech, gaming and financial services companies explain how they succeed in their inter partes reviews and covered business method actions to invalidate broad patents filed by non-practising entities. Read more... 

Inventive step: pharma innovators say "routine testing is never routine"

After the UK Supreme Court's ruling in Acatvis v Icos, pharma innovators say there is no such thing as routine testing and that it is difficult to discern what might be considered obvious in dosage regimens. Read more... 

Sign up to receive more content like this in Patent Strategy’s weekly newsletter.




more from across site and SHARED ros bottom lb

More from across our site

AIPPI has pulled the plug on its planned 2027 World Congress, and INTA has seemingly committed to hosting a meeting there, but the concerns won’t abate
Despite being outspent by a wealthy opponent, a trial attorney at King & Spalding says ‘relentless pursuit of the truth’ helped his team secure a $420m damages award for mobile gaming client
190 drugs face loss of exclusivity between 2026 and 2030, with the list including Bristol Myers Squibb’s blood-thinning drug Eliquis and immunotherapy medication Opdivo
Nokia, represented by a team from Bird & Bird, adjudged to have made fair offer to Asus and Acer in UK SEP dispute
Azhar Sadique and Kane Ridley, who founded the London office in 2023, are now both working in legal tech and AI-related roles, while another UK-based lawyer has also left
Partner Pierre Pérot rejoins the firm he left in 2022 alongside another returning lawyer, associate Camille Abba
Vaping dispute, in which Stobbs and Brandsmiths are the representatives, tested how the UK's Human Rights Act can apply to injunctions restraining unjustified threats
An AI platform being sold for £40m, and lateral hires involving law firms Womble Bond Dickinson and Cadwell Thomas were among the top talking points
With the London Annual Meeting behind us, we look back at some of the lessons learned this week and ahead to what 2027 will bring
In-house counsel aren’t impressed with law firms’ international networks, but practitioners say they are crucial for business
Gift this article